Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJin ZhouTYTao YouYWYun Wang

Discussion

Loading...

Member takes

Overview

Single-center study demonstrates safety and efficacy of glofitamab as bridging therapy before CAR-T in large B-cell lymphoma patients.

Key Points

  • The aim was to investigate the safety and efficacy of glofitamab bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma patients.
  • Single-center study evaluated glofitamab as bridging therapy in relapsed/refractory large B-cell lymphoma patients
  • All eligible patients received glofitamab before stem cell transplant and CAR-T therapy
  • Responses to glofitamab were assessed using standard criteria (CR, PR, SD, PD)
  • Safety monitored for CRS and ICANS, with survival outcomes analyzed
  • Statistical analysis included descriptive statistics and median follow-up via reverse Kaplan-Meier estimation.
  • 75% overall response rate post-CAR-T therapy, with 50% achieving complete response
  • 90% 6-month progression-free survival and 100% overall survival
  • Cytokine release syndrome was the most common adverse event; no Grade ≥2 events reported
  • Adverse events led to no treatment discontinuation; all events resolved
  • No significant change in effector T cell function before and after glofitamab.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fahttps://doi.org/10.1182/blood-2025-7256
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  2. 2Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  3. 3Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations